• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Myovant shows disappointing prostate cancer data on the way to the FDA, stock sinks

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 29, 2020 at 12:22: PM
via Myovant $MYOV has been prepping relugolix for advanced prostate cancer over the last several months, looking to improve upon the old standard in AbbVie’s Lupron. But new data out Tuesday will not help its cause.

article source
 




Top Bottom
Back
Quote